Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 14;11(1):332-341.
doi: 10.1159/000545604. eCollection 2025 Jan-Dec.

Urinary Myeloid Bodies as a Biomarker for Early Diagnosis and Monitoring of Enzyme Replacement Therapy in Fabry Disease

Junlan Yang  1   2 , Zhiyuan Wei  1   2 , Haifeng Ni  1 , Qianqian Wu  1   2 , Siqi Peng  1   2 , Wen Shi  1   2 , Xiaoxu Wang  1   2 , Yan Yang  1 , Jianan Jiang  2 , Jingyuan Cao  3 , Yao Wang  4 , Liyuan Zhang  5 , Aihua Zhang  6 , Xiaoliang Zhang  1 , Bin Wang  1
Affiliations

Urinary Myeloid Bodies as a Biomarker for Early Diagnosis and Monitoring of Enzyme Replacement Therapy in Fabry Disease

Junlan Yang et al. Kidney Dis (Basel). .

Abstract

Introduction: The prevalence of urinary myeloid bodies in Fabry disease patients and their correlation with renal involvement remains unclear.

Methods: This single-center, retrospective study included 25 patients with Fabry disease and 27 controls. We analyzed 24-h urine samples for the presence of urinary myeloid bodies and evaluated clinical data, including serum creatinine, estimated glomerular filtration rate (eGFR), 24-h urinary protein levels, α-Gal A, and Lyso-GL-3. Seven Fabry patients underwent analysis of urine samples before and after 1 year of enzyme replacement therapy (ERT).

Results: Urinary myeloid bodies were detected in 84% of Fabry patients (21 out of 25), with no significant gender differences. None of the healthy controls or patients with other renal disease patients had urinary myeloid bodies. Among the Fabry patients with myeloid bodies, 48% had no proteinuria, and 52% were in CKD1 stage G1. Furthermore, urinary myeloid bodies were detected in 4 patients under the age of 20, despite the absence of or only minimal proteinuria, and these patients all exhibited a substantial number of myeloid bodies. After 1 year of ERT, significant reductions in both the count (p = 0.043) and area ratio (p = 0.028) of myeloid bodies were observed.

Conclusion: Urinary myeloid bodies are specific to Fabry disease and are associated with early renal injury, even in the absence of proteinuria. These findings suggest that urinary myeloid bodies may serve as a noninvasive biomarker for the early diagnosis of Fabry disease and for monitoring the efficacy of ERT.

Keywords: Fabry disease; Hereditary disease; Urinary myeloid bodies.

PubMed Disclaimer

Conflict of interest statement

All the authors declared no competing interests.

Figures

Fig. 1.
Fig. 1.
Quantitative analysis of urinary myeloid bodies.
Fig. 2.
Fig. 2.
Typical morphology of urine myeloid bodies in Fabry patients under transmission electron microscopy. a–c Transmission electron microscopy images showing typical structures of urinary myeloid bodies (scale bar, 2.0 μm). d–f Higher magnification images revealing the multilamellar concentric myelin-like structures of urinary myeloid bodies (scale bar, 200 nm).
Fig. 3.
Fig. 3.
Sector diagram of urinary myeloid bodies and proteinuria in Fabry patients.
Fig. 4.
Fig. 4.
Internal subgroup analysis of patients with urinary myeloid bodies. a Gender distribution. b Age distribution. c Proteinuria status distribution. d Distribution across stages of chronic kidney disease (CKD).
Fig. 5.
Fig. 5.
Quantitative changes in urinary myeloid bodies in Fabry patients after 1 year of ERT, showing alterations in number (a) and area ratio (b).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. . European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189–203. - PubMed
    1. Germain DP, Altarescu G, Barriales-Villa R, Mignani R, Pawlaczyk K, Pieruzzi F, et al. . An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137(1–2):49–61. - PubMed
    1. Li X, Ren X, Zhang Y, Ding L, Huo M, Li Q. Fabry disease: mechanism and therapeutics strategies. Front Pharmacol. 2022;13:1025740. - PMC - PubMed
    1. Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, et al. . Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631–41. - PMC - PubMed
    1. Izhar R, Borriello M, La Russa A, Di Paola R, De A, Capasso G, et al. . Fabry disease in women: genetic basis, available biomarkers, and clinical manifestations. Genes. 2023;15(1):37. - PMC - PubMed